|
Vitaxin is a humanized monoclonal antibody against the vascular integrin anb3[1]. It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. At this time Vitaxin is in Phase II trial which is where the dose has already been proven safe in Phase I, and has been ramped up to test therapeutic levels in human participants. It is currently in clinical trials as a treatment for colorectal cancer.
References
- ^ Vande Woude, 27
- F. Vande Woude, George; George Klein (2000). Advances in Cancer Research. Academic Press, 27. ISBN 978-0120066797.
| |
